Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial
Tirzepatide targets the GLP-1 receptor and another hormone called GIP
Rotate injection sites systematically (abdomen, thigh, or upper arm) to prevent lipohypertrophy or lipoatrophy
Contact your healthcare provider if you experience: Absent periods (amenorrhea): Missing three or more consecutive menstrual cycles if previously regular, or six or more months if previously irregular Heavy bleeding (menorrhagia): Soaking through a pad or tampon every hour for several consecutive hours, or periods lasting longer than seven days Severe pain: New or worsening menstrual cramping not relieved by over-the-counter medications Intermenstrual bleeding: Bleeding or spotting between periods that persists beyond initial treatment months Pregnancy possibility: Any missed period when pregnancy is possible, as tirzepatide is not recommended during pregnancy Urgent warning signs: Heavy bleeding with dizziness, fainting, rapid heartbeat, or severe weakness requires emergency evaluation Your healthcare provider may recommend specific investigations to evaluate persistent menstrual irregularities
In addition to focusing on new indications, Merck is also betting on Keytruda's combination therapies
